UiPath Inc vs Synopsys, Inc. — how do they compare? UiPath Inc trades at $13.48 (market cap $6.91B), while Synopsys, Inc. trades at $509.99 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 13.8× UiPath Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Synopsys, Inc. for 71 Days on average.
| PATH | SNPS | |
|---|---|---|
Market Cap | $6.91B | $95.39B |
Volume | 34,321,250 | 3,374,903 |
Sector | Technology | Technology |
52-Week High | $19.29 | $534.56 |
52-Week Low | $9.38 | $367.70 |
Typical Hold Time | 139 Days | 71 Days |
Enterprise Value | $5.70B | $102.62B |
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.38% today, with a bullish technical signal from moving averages despite neutral oscillators. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while narrowing net losses from -$74M to projected $362M profit. Recent partnerships with Snowflake and BDO highlight strategic expansion in AI orchestration capabilities.
PATH offers compelling value at current levels with 14% upside to consensus price target of $15.13. Strong enterprise AI adoption and improved profitability outlook support growth, though execution risks and competitive pressures in automation software warrant monitoring. The stock presents a balanced risk-reward profile for investors seeking automation exposure.
Synopsys (SNPS) trades at $497.75, down 0.98% on the day, but maintains strong momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Recent AI partnerships with OpenAI and Amazon, along with raised 2027 guidance, have driven significant investor optimism and a 13% surge in early October 2026.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus price target representing 15% upside. Key risks include high valuation multiples (P/E 86.87) and integration challenges from the Ansys acquisition. Revenue growth acceleration to $9.4B projected for 2026 and expanding AI-driven chip design opportunities support the bullish case, though investors should monitor execution on ambitious growth targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →